A prospective clinical study in 283 patients found that an automated rRNA-based assay provided higher sensitivity and different clearance kinetics compared with smear microscopy for monitoring tuberculosis treatment. The work supports the direction toward more quantitative and automation-friendly approaches for therapy response monitoring. By tracking clearance patterns, the study addresses a persistent clinical problem: smears can miss low bacillary burden and may lag behind molecular clearance signals. For TB programs, assay performance and feasibility will be central to whether rRNA testing becomes part of routine monitoring protocols. The clinical implication is straightforward—more reliable monitoring tools could help tailor adherence and escalation decisions earlier in the treatment course.